Testing pembrolizumab for long COVID brain symptoms
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests whether a drug called pembrolizumab (a type of immunotherapy) can help people with ongoing neurological symptoms after COVID-19. The goal is to see if it is safe and possibly improves symptoms like brain fog, fatigue, and dizziness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and had a positive COVID-19 test that led to long COVID symptoms.
- Your COVID-19 illness was mild to moderate (you were not hospitalized in the ICU).
- You have had neurological symptoms like brain fog, fatigue, or dizziness for at least 6 months.
- Symptoms must be moderate to severe (score of 3 or more on a long COVID symptom scale).
- You cannot have certain other medical conditions like heart failure, COPD, fibromyalgia, or chronic fatigue syndrome (ME/CFS).
- You agree not to get any vaccines during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET scan to look at brain inflammation in people with neurological symptoms after COVID-19. It aims to understand how inflammation might be linked to ongoing problems like brain fog or memory issues.
This trial uses brain scans to understand why people with long COVID feel very tired or have trouble thinking clearly. It could help find new treatments for these symptoms.
This Phase 2 trial tests whether intravenous immunotherapy (IVIG) can improve ongoing neurologic symptoms after a mild-to-moderate COVID-19 illness. It targets people with persistent symptoms such as brain fog, fatigue, trouble thinking, dizziness when standing, and balance or other neurologic problems.
This trial studies if brain scans can help understand 'brain fog' in Long COVID. It also looks at how a gentle magnetic stimulation might affect symptoms. If you have ongoing thinking problems after COVID, this study may help find new ways to help.
This trial studies people who had COVID-19 to understand why some develop long-term symptoms while others recover fully. It aims to find links between the immune system and brain changes using imaging.
This trial tests whether the anti-inflammatory drug baricitinib can improve persistent long COVID symptoms like brain fog, fatigue, and shortness of breath. You may qualify if you had COVID-19 at least 6 months ago and still have bothersome symptoms that affect your daily life.
Hear when a new Post-Acute COVID-19 Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.